LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 31.35M shares rose 13.9% year over year, ahead of the +10.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +54.3% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +13.9% holds above the trailing-twelve-month pace of +10.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 28.81M USD
- Year-over-year change
- +35.4%
- 4-year CAGR
- +36.6%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.81M | +35.4% |
| FY2024 | 2024-12-31 | 21.28M | +161.3% |
| FY2023 | 2023-12-31 | 8.15M | +3.9% |
| FY2022 | 2022-12-31 | 7.84M | -5.4% |
| FY2021 | 2021-12-31 | 8.29M | — |
Weighted Avg Shares (Diluted) vs competitors
How LENZ compares with its peers on the latest reported figures
- LENZ's LTM Mar 2026 weighted avg shares (diluted) of 29.76M shares is the lowest of the 11 companies compared; the peer median is 123.71M shares.
- Its year-over-year change of +10.4% is the 5th highest of 11, against a peer median of +2.4%.
- Over three fiscal years its annual growth of +54.3% compares with a peer median of +12.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 667.45M | +1.6% | +20.5% | |
| LTM Mar 2026 | 227.14M | +12.3% | +13.3% | |
| LTM Mar 2026 | 192.75M | +1.8% | +8.3% | |
| LTM Mar 2026 | 153.89M | +26.0% | +15.2% | |
| LTM Jun 2026 | 146.04M | +2.7% | +3.3% | |
| LTM Mar 2026 | 101.37M | +55.6% | +57.4% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | 98.76M | +1.3% | +35.1% |
| LTM Mar 2026 | 62.03M | +15.9% | +5.5% | |
| LTM Mar 2026 | 60.14M | +2.0% | +12.5% | |
| FY2025 | 47.82M | +1.2% | +11.1% | |
| LTM Mar 2026 | 29.76M | +10.4% | +54.3% | |
| Peer median (excluding LENZ) | 123.71M | +2.4% | +12.9% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.